Compare GSAT & PRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GSAT | PRAX |
|---|---|---|
| Founded | 2003 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.2B | 9.6B |
| IPO Year | 2006 | 2020 |
| Metric | GSAT | PRAX |
|---|---|---|
| Price | $61.54 | $325.47 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 15 |
| Target Price | $62.00 | ★ $572.13 |
| AVG Volume (30 Days) | ★ 525.8K | 364.5K |
| Earning Date | 06-01-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 74.58 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $112,660,000.00 | N/A |
| Revenue This Year | $10.93 | N/A |
| Revenue Next Year | $10.78 | $6,395.88 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $17.24 | $26.70 |
| 52 Week High | $74.88 | $354.87 |
| Indicator | GSAT | PRAX |
|---|---|---|
| Relative Strength Index (RSI) | 52.84 | 53.52 |
| Support Level | $55.85 | $290.36 |
| Resistance Level | $65.94 | N/A |
| Average True Range (ATR) | 3.78 | 18.34 |
| MACD | 0.31 | -2.56 |
| Stochastic Oscillator | 69.69 | 57.24 |
Globalstar Inc is a telecommunications company that derives revenue from the provision of mobile satellite services. Mobile satellite services are typically used by customers where existing terrestrial wireline and wireless communications networks are impaired or do not exist. The company provides communications services such as two-way voice and data transmission. In addition, one-way data transmission is also offered. Both services are offered using mobile or fixed devices. The company is an owner of satellite assets. It has one reportable segment: MSS business. The company generates the vast majority of its revenue within the United States.
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. It is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company applies genetic insights to the discovery and development of therapies for neurological disorders through two proprietary platforms: Cerebrum and Solidus. It has established a diversified, multimodal CNS portfolio with four clinical-stage product candidates across movement disorders and epilepsy, which include Ulixacaltamide, Relutrigine, Vormatrigine, and Elsunersen. The firm operates in only one segment and is focused on discovering and developing therapies for CNS disorders.